Literature DB >> 18780946

Saccharomyces boulardii effects on gastrointestinal diseases.

Galliano Zanello1, Francois Meurens, Mustapha Berri, Henri Salmon.   

Abstract

Health benefits attributed to probiotics have been described for decades. They include the treatment and the prevention of gastrointestinal diseases, vaginal and urinary infections and allergies. Saccharomyces boulardii, a species of yeast widely distributed, has been described as a biotherapeutic agent since several clinical trials displayed its beneficial effects in the prevention and the treatment of intestinal infections and in the maintenance of inflammatory bowel disease. All these diseases are characterized by acute diarrhoea. Administration of the yeast in combination or not with an antibiotherapy has shown to decrease significantly the duration and the frequency of diarrhoea. Experimental studies elucidated partially the molecular mechanisms triggered to improve the host health. The discovery of its anti-inflammatory and immuno-modulatory activities in correlation with the advances in the understanding of mucosal immunology opens a new field of perspectives in S. boulardii therapeutic applications.

Entities:  

Mesh:

Year:  2008        PMID: 18780946

Source DB:  PubMed          Journal:  Curr Issues Mol Biol        ISSN: 1467-3037            Impact factor:   2.081


  30 in total

Review 1.  Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists.

Authors:  P Frey-Klett; P Burlinson; A Deveau; M Barret; M Tarkka; A Sarniguet
Journal:  Microbiol Mol Biol Rev       Date:  2011-12       Impact factor: 11.056

2.  β-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells.

Authors:  Roger Badia; M Teresa Brufau; Ana Maria Guerrero-Zamora; Rosil Lizardo; Irina Dobrescu; Raquel Martin-Venegas; Ruth Ferrer; Henri Salmon; Paz Martínez; Joaquim Brufau
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

3.  Evaluation of the Probiotic Potential of Saccharomyces cerevisiae Strain (C41) Isolated from Tibicos by In Vitro Studies.

Authors:  Haydee Eliza Romero-Luna; Humberto Hernández-Sánchez; Rosa María Ribas-Aparicio; Patricia Isidra Cauich-Sánchez; Gloria Dávila-Ortiz
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

4.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

5.  Yeasts from kefir grains: isolation, identification, and probiotic characterization.

Authors:  Gabriela Diosma; David E Romanin; María F Rey-Burusco; Alejandra Londero; Graciela L Garrote
Journal:  World J Microbiol Biotechnol       Date:  2013-07-04       Impact factor: 3.312

6.  In Vitro Properties of Potential Probiotic Indigenous Yeasts Originating from Fermented Food and Beverages in Taiwan.

Authors:  Ruo-Ting Hsiung; Wei-Ta Fang; Ben A LePage; Shih-An Hsu; Chia-Hsuan Hsu; Jui-Yu Chou
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

7.  In Vitro Assessment of Probiotic Potential of Saccharomyces Cerevisiae DABRP5 Isolated from Bollo Batter, a Traditional Goan Fermented Food.

Authors:  Rochelle Prunella Pereira; Reshma Jadhav; Abhishek Baghela; Delicia Avilla Barretto
Journal:  Probiotics Antimicrob Proteins       Date:  2021-01-17       Impact factor: 4.609

8.  Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state.

Authors:  Alexandra Canonici; Emilie Pellegrino; Carole Siret; Chloé Terciolo; Dorota Czerucka; Sonia Bastonero; Jacques Marvaldi; Dominique Lombardo; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

9.  S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.

Authors:  Vincent Cascio; Daniel Gittings; Kristen Merloni; Matthew Hurton; David Laprade; Nicanor Austriaco
Journal:  BMC Microbiol       Date:  2013-02-13       Impact factor: 3.605

10.  Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Authors:  D Ortuño Sahagún; A L Márquez-Aguirre; S Quintero-Fabián; R I López-Roa; A E Rojas-Mayorquín
Journal:  PPAR Res       Date:  2012-11-28       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.